Dec 5 (Reuters) - MediciNova Inc MNOV.O:
MEDICINOVA PRESENTS STUDY UPDATE AND INTERIM ANALYSIS OF PHASE 2/3 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS (COMBAT-ALS CLINICAL TRIAL) AT THE 35TH INTERNATIONAL SYMPOSIUM ON ALS/MND
MEDICINOVA INC - POSITIVE CORRELATIONS OBSERVED BETWEEN 6-MONTH AND 12-MONTH DATA
MEDICINOVA INC - EXPECTS TO COMPLETE PATIENT ASSIGNMENTS BY JUNE 2025 WITH TRIAL RESULTS EXPECTED IN 2026
Source text: ID:nGNX72vMw4
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.